Progesterone
Catalog No.S1705
Molecular Weight(MW): 314.46
Progesterone is an endogenous steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species. A potent agonist of the nuclear progesterone receptor (nPR) with Kd of 1 nM; An agonist of the membrane progesterone receptors(mPRs); An antagonist of the σ1 receptor.
Cited by 1 Publication
1 Customer Review
-
SPOP inhibits progesterone-induced S phase entry and Erk1/2 activation. (A) T47D cells were transfected with control or Myc-SPOP constructs. After 24 hr, cells were treated with the vehicle ethanol (EtOH) or progesterone (10 nM) for 24 hr. The cell cycle percentages was determined by PI staining and FACS; (B) T47D cells were transfected with control siRNAs or SPOP-specific siRNAs. After 48 hr, cells were treated and analyzed as in (A); (C) T47D cells were transfected with control or Myc-SPOP constructs. After 24 hr, cells were treated with the vehicle ethanol (EtOH) or progesterone (10 nM) for indicated times. Cell lysates were prepared for WB analyses; (D) T47D cells were transfected with control or SPOP-specific siRNA. After 48 hr, cells were treated and analyzed as in (C).
Am J Cancer Res, 2015, 5(10): 3210-3220.. Progesterone purchased from Selleck.
Purity & Quality Control
Choose Selective Estrogen/progestogen Receptor Inhibitors
Biological Activity
| Description | Progesterone is an endogenous steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species. A potent agonist of the nuclear progesterone receptor (nPR) with Kd of 1 nM; An agonist of the membrane progesterone receptors(mPRs); An antagonist of the σ1 receptor. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Targets |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| In vitro |
Progesterone has biphasic effects on proliferation of breast cancer cells; it stimulates growth in the first cell cycle, then arrests cells at G1/S of the second cycle accompanied by up-regulation of the cyclin-dependent kinase inhibitor, p21. Progesterone-mediated transcription is further prevented by overexpression of E1A, suggesting that CBP/p300 is required. [1] Progesterone drives a series of events where luminal cells probably provide Wnt4 and RANKL signals to basal cells which in turn respond by upregulating their cognate receptors, transcriptional targets and cell cycle markers. [2] Progesterone treatment increases the sensitivity of cortical synaptoneurosomes to GABA (i.e., decreased the EC50) and increases the maximal efficacy with which GABA stimulated Cl- transport (i.e., increased the Emax). [3] |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cell Data |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| In vivo | Progesterone blocks the beneficial effect of estrogen on Abeta accumulation but not on behavioral performance in female 3xTg-AD mice. Progesterone significantly reduces tau hyperphosphorylation when administered both alone and in combination with estrogen. [4] Progesterone-treated rats are less impaired on a Morris water maze spatial navigation task than rats treated with the oil vehicle. Progesterone-treated rats also show less neuronal degeneration 21 days after injury in the medial dorsal thalamic nucleus, a structure that has reciprocal connections with the contused area. [5] |
Protocol
Solubility (25°C)
| In vitro | Ethanol | 63 mg/mL (200.34 mM) |
|---|---|---|
| DMSO | 22 mg/mL (69.96 mM) | |
| Water | Insoluble |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 314.46 |
|---|---|
| Formula | C21H30O2 |
| CAS No. | 57-83-0 |
| Storage | powder |
| in solvent | |
| Synonyms | N/A |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03309709 | Recruiting | Endometrial Polyp | University Magna Graecia | October 8 2017 | Phase 3 |
| NCT03272412 | Recruiting | Ongoing Pregnancy Rate | Instituto Valenciano de Infertilidad IVI VALENCIA | September 8 2017 | -- |
| NCT03297216 | Recruiting | Pre-term Birth|HIV-1-infection | University of North Carolina Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|AMAG Pharmaceuticals Inc.|Bill and Melinda Gates Foundation | February 7 2018 | Phase 3 |
| NCT03174691 | Completed | Infertility | Vietnam National University|Mỹ Đức Hospital | June 7 2017 | Not Applicable |
| NCT02817464 | Active not recruiting | Pregnancy|Contraception | Teva Branded Pharmaceutical Products R&D Inc.|FHI 360|Teva Pharmaceutical Industries | October 7 2016 | Phase 1 |
| NCT02685072 | Recruiting | Smoking Cessation | Yale University|National Cancer Institute (NCI) | April 7 2016 | Phase 4 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
